Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by β-lactam-susceptible and highly resistant pneumococci.

Abstract

Therapeutic alternatives are needed against infections caused by highly multidrug-resistant Streptococcus pneumoniae. Novobiocin, an old antibiotic, was tested in vitro and in a murine sepsis model against one amoxicillin-susceptible and three amoxicillin-resistant strains [minimum inhibitory concentrations (MICs) 8–64mg/L]. Novobiocin MICs for all strains were 0.25–0.5mg/L. In sepsis, novobiocin and amoxicillin were evaluated at 25, 50, 100 and 200mg/kg given at 1, 5, 24 and 48h post bacterial challenge. The most effective regimens in animals infected with the amoxicillin-susceptible strain were 200mg/kg novobiocin and 25mg/kg amoxicillin, achieving 100% survival and undetectable organisms in the peritoneum. Among mice infected with amoxicillin-resistant S. pneumoniae, 200mg/kg novobiocin gave the highest protection (90–100% survivors), followed by 200mg/kg amoxicillin (60–100%), 100mg/kg novobiocin (50–87.5%) and 50mg/kg amoxicillin (14.3–25%). The killing effect of antibiotics in the peritoneum (mean Δlog10 colony-forming units/mL between treated and control mice) was as follows: 200mg/kg novobiocin (−6.6)>200mg/kg amoxicillin (−5.6)>100mg/kg novobiocin (−3.7)>50mg/kg amoxicillin (−0.7). Total plasma and ultrafiltrate pharmacokinetics of novobiocin (200mg/kg, single dose) in non-infected mice showed, respectively, half-lives of 151min and 215min, area under the concentration–time curves (AUCs) of 945.0mg h/L and 136.6mg h/L and maximal concentrations of 147mg/L and 18mg/L. Novobiocin may be a promising agent for therapy of highly β-lactam-resistant pneumococcal infections.